| Mr Jeremy Dean Morris, CRNA | |
|
815 E Parrish Ave, Suite 460, Owensboro, KY 42303-3222 | |
| (270) 684-5005 | |
| (270) 926-4432 |
| Full Name | Mr Jeremy Dean Morris |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 21 Years |
| Location | 815 E Parrish Ave, Owensboro, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245277557 | NPI | - | NPPES |
| 74007501 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 4174A (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohio County Hospital | Hartford, KY | Hospital |
| Memorial Hospital And Health Care Center | Jasper, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohio County Hospital Corporation | 3577477264 | 66 |
| Little Company Of Mary Hospital Of Indiana Inc | 4587578042 | 167 |
News Archive
Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
Using a mouse model of necrotizing enterocolitis - a potentially fatal condition that causes a premature infant's gut to suddenly die - researchers at Johns Hopkins say they have uncovered the molecular causes of the condition and its associated brain injury.
A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.
› Verified 7 days ago
| Entity Name | Anesthesia Care Enterprises Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861450371 PECOS PAC ID: 0840104899 Enrollment ID: O20031114000300 |
News Archive
Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
Using a mouse model of necrotizing enterocolitis - a potentially fatal condition that causes a premature infant's gut to suddenly die - researchers at Johns Hopkins say they have uncovered the molecular causes of the condition and its associated brain injury.
A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.
› Verified 7 days ago
| Entity Name | Northstar Anesthesia Of Kentucky, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386938900 PECOS PAC ID: 8628248069 Enrollment ID: O20110823000443 |
News Archive
Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
Using a mouse model of necrotizing enterocolitis - a potentially fatal condition that causes a premature infant's gut to suddenly die - researchers at Johns Hopkins say they have uncovered the molecular causes of the condition and its associated brain injury.
A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.
› Verified 7 days ago
| Entity Name | Environ Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831438092 PECOS PAC ID: 3870717754 Enrollment ID: O20140616001501 |
News Archive
Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
Using a mouse model of necrotizing enterocolitis - a potentially fatal condition that causes a premature infant's gut to suddenly die - researchers at Johns Hopkins say they have uncovered the molecular causes of the condition and its associated brain injury.
A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.
› Verified 7 days ago
| Entity Name | Ohio County Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740812031 PECOS PAC ID: 3577477264 Enrollment ID: O20200511001913 |
News Archive
Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
Using a mouse model of necrotizing enterocolitis - a potentially fatal condition that causes a premature infant's gut to suddenly die - researchers at Johns Hopkins say they have uncovered the molecular causes of the condition and its associated brain injury.
A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jeremy Dean Morris, CRNA 6401 Boston Laffoon Rd, Philpot, KY 42366-9314 Ph: (270) 684-5005 | Mr Jeremy Dean Morris, CRNA 815 E Parrish Ave, Suite 460, Owensboro, KY 42303-3222 Ph: (270) 684-5005 |
News Archive
Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
Using a mouse model of necrotizing enterocolitis - a potentially fatal condition that causes a premature infant's gut to suddenly die - researchers at Johns Hopkins say they have uncovered the molecular causes of the condition and its associated brain injury.
A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.
› Verified 7 days ago
Carla Ann Atherton, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 815 E Parrish Ave, Suite 460, Owensboro, KY 42303 Phone: 270-684-5005 | |
Mr. John A Keller, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 815 E Parrish Ave, Suite 460, Owensboro, KY 42303 Phone: 270-684-5005 Fax: 270-926-4432 | |
Daniel L Huther, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2900 Veach Rd, Ste 3, Owensboro, KY 42303 Phone: 270-684-5005 | |
Lisa A Scheller, APRN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-2000 | |
Jonathan Embry, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-2000 | |
Mrs. Haley T Morris, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 815 E Parrish Ave, Suite 460, Owensboro, KY 42303 Phone: 270-684-5005 Fax: 270-926-4432 |